297 related articles for article (PubMed ID: 10426539)
1. GM1 ganglioside restores dopaminergic neurochemical and morphological markers in aged rats.
Goettl VM; Wemlinger TA; Duchemin AM; Neff NH; Hadjiconstantinou M
Neuroscience; 1999; 92(3):991-1000. PubMed ID: 10426539
[TBL] [Abstract][Full Text] [Related]
2. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
Hadjiconstantinou M; Mariani AP; Neff NH
Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
[TBL] [Abstract][Full Text] [Related]
3. Acute and repeated administration of fluphenazine-N-mustard alters levels of tyrosine hydroxylase mRNA in subsets of mesencephalic dopaminergic neurons.
Weiss-Wunder LT; Chesselet MF
Neuroscience; 1992 Jul; 49(2):297-305. PubMed ID: 1359452
[TBL] [Abstract][Full Text] [Related]
4. Motoric behavior in aged rats treated with GM1.
Goettl VM; Wemlinger TA; Colvin AE; Neff NH; Hadjiconstantinou M
Brain Res; 2001 Jul; 906(1-2):92-100. PubMed ID: 11430865
[TBL] [Abstract][Full Text] [Related]
5. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
Rothblat DS; Schneider JS
Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
[TBL] [Abstract][Full Text] [Related]
6. GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse.
Schneider JS; Smith MG; DiStefano L; Berrian J
Brain Res; 1994 Feb; 636(2):353-6. PubMed ID: 7912161
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
8. GM1 ganglioside improves dopaminergic markers of rat mesencephalic cultures treated with MPP+.
Dalia A; Neff NH; Hadjiconstantinou M
J Neurosci; 1993 Jul; 13(7):3104-11. PubMed ID: 8101212
[TBL] [Abstract][Full Text] [Related]
9. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Schneider JS; Kean A; DiStefano L
J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
[TBL] [Abstract][Full Text] [Related]
10. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection.
Lapchak PA; Beck KD; Araujo DM; Irwin I; Langston JW; Hefti F
Neuroscience; 1993 Apr; 53(3):639-50. PubMed ID: 8098137
[TBL] [Abstract][Full Text] [Related]
11. Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat.
Toffano G; Savoini GE; Moroni F; Lombardi G; Calzà L; Agnati LF
Brain Res; 1984 Apr; 296(2):233-9. PubMed ID: 6142756
[TBL] [Abstract][Full Text] [Related]
12. On the altered expression of tyrosine hydroxylase and calbindin-D 28kD immunoreactivities and viability of neurons in the ventral tegmental area of Tsai following injections of 6-hydroxydopamine in the medial forebrain bundle in the rat.
Tan Y; Williams EA; Lancia AJ; Zahm DS
Brain Res; 2000 Jun; 869(1-2):56-68. PubMed ID: 10865059
[TBL] [Abstract][Full Text] [Related]
13. Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells.
Alabi AO; Ajayi AM; Ben-Azu B; Omorobge O; Umukoro S
Metab Brain Dis; 2019 Dec; 34(6):1723-1736. PubMed ID: 31463866
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatment with GM1 ganglioside improves survival and function of cryopreserved embryonic midbrain grafted to the 6-hydroxydopamine-lesioned rat striatum.
Sautter J; Höglinger GU; Oertel WH; Earl CD
Exp Neurol; 2000 Jul; 164(1):121-9. PubMed ID: 10877922
[TBL] [Abstract][Full Text] [Related]
15. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
16. Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons.
Burke RE; Macaya A; DeVivo D; Kenyon N; Janec EM
Neuroscience; 1992 Oct; 50(3):559-69. PubMed ID: 1359461
[TBL] [Abstract][Full Text] [Related]
17. GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism.
Schneider JS; Yuwiler A
Exp Neurol; 1989 Aug; 105(2):177-83. PubMed ID: 2568945
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic development of prenatal ventral mesencephalon and striatum in organotypic co-cultures.
Lyng GD; Snyder-Keller A; Seegal RF
Brain Res; 2007 Feb; 1133(1):1-9. PubMed ID: 17196555
[TBL] [Abstract][Full Text] [Related]
19. Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
Schneider JS; DiStefano L
Brain Res; 1995 Mar; 674(2):260-4. PubMed ID: 7796105
[TBL] [Abstract][Full Text] [Related]
20. Exogenous GM1 gangliosides induce partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice.
Date I; Felten SY; Felten DL
Neurosci Lett; 1989 Dec; 106(3):282-6. PubMed ID: 2601883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
